Neuropsychiatric disorders in Cushing's syndrome
- PMID: 20829621
- DOI: 10.1159/000314317
Neuropsychiatric disorders in Cushing's syndrome
Abstract
Glucocorticoids are crucial in the initiation and consolidation of the stress response. Patients with active Cushing's syndrome (CS) are exposed to excessive endogenous glucocorticoid levels. In these patients, psychopathology is often being observed. The most common co-morbid disorder is major depression, but to a lesser extent mania and anxiety disorders have also been reported. A severe clinical presentation of CS often also includes depression. Reduction of glucocorticoid synthesis or action, either with metyrapone, ketoconazole, or mifepristone, rather than treatment with antidepressant drugs, is generally successful in relieving depressive symptoms, as well as other disabling symptoms. Following successful surgical treatment of hypercortisolism, both physical and psychiatric signs and symptoms improve substantially. However, it appears that patients do not completely return to their premorbid level of functioning and persistent impairment of quality of life and cognitive function has been reported despite long-term cure. At present, it is not clear whether, and to which extent, psychopathology still affects general well-being after long-term cure of CS.
Copyright © 2010 S. Karger AG, Basel.
Similar articles
-
Medical treatment of Cushing's syndrome: glucocorticoid receptor antagonists and mifepristone.Neuroendocrinology. 2010;92 Suppl 1:125-30. doi: 10.1159/000314224. Epub 2010 Sep 10. Neuroendocrinology. 2010. PMID: 20829633
-
Mifepristone: treatment of Cushing's syndrome.Clin Obstet Gynecol. 1996 Jun;39(2):506-10. doi: 10.1097/00003081-199606000-00024. Clin Obstet Gynecol. 1996. PMID: 8734015 Review.
-
The use of the glucocorticoid receptor antagonist mifepristone in Cushing's syndrome.Curr Opin Endocrinol Diabetes Obes. 2012 Aug;19(4):295-9. doi: 10.1097/MED.0b013e32835430bf. Curr Opin Endocrinol Diabetes Obes. 2012. PMID: 22543346 Review.
-
Mifepristone for management of Cushing's syndrome.Pharmacotherapy. 2013 Mar;33(3):319-29. doi: 10.1002/phar.1202. Epub 2013 Feb 21. Pharmacotherapy. 2013. PMID: 23436494 Review.
-
Psychiatric manifestations of Cushing's syndrome: response to lowering of plasma cortisol.Q J Med. 1979 Jul;48(191):465-72. Q J Med. 1979. PMID: 542586
Cited by
-
Improvement in cognitive impairment following the successful treatment of endogenous Cushing's syndrome-a case report and literature review.BMC Endocr Disord. 2019 Jun 28;19(1):68. doi: 10.1186/s12902-019-0401-4. BMC Endocr Disord. 2019. PMID: 31253144 Free PMC article. Review.
-
Neurocognitive Functions and Brain Volume in Patients with Endogenous Cushing's Syndrome Before and After Curative Surgery.Indian J Endocrinol Metab. 2020 Sep-Oct;24(5):396-401. doi: 10.4103/ijem.IJEM_162_20. Epub 2020 Nov 9. Indian J Endocrinol Metab. 2020. PMID: 33489843 Free PMC article.
-
Patient and Provider Perspectives on Postsurgical Recovery of Cushing Syndrome.J Endocr Soc. 2021 Jun 14;5(8):bvab109. doi: 10.1210/jendso/bvab109. eCollection 2021 Aug 1. J Endocr Soc. 2021. PMID: 34195531 Free PMC article.
-
Recent developments in drug therapy for Cushing's disease.Drugs. 2013 Jun;73(9):907-18. doi: 10.1007/s40265-013-0067-6. Drugs. 2013. PMID: 23737437 Review.
-
Glucocorticoid and Mineralocorticoid Receptors in the Brain: A Transcriptional Perspective.J Endocr Soc. 2019 Jul 24;3(10):1917-1930. doi: 10.1210/js.2019-00158. eCollection 2019 Oct 1. J Endocr Soc. 2019. PMID: 31598572 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical